In the same study concerning MDD, researchers found the significantly upregulated level of Nrf2 in the nucleus, and the increasing trend of HO-1 and NQO-1, the Nrf2-downstream antioxidant genes, in NBP treatment [26], consistent with results from the experiment about OGD under NBP administration [77]. The gene discussed is NFE2L2; the disease is major depressive disorder.